A citation-based method for searching scientific literature

Shumei Kato, Ki Hwan Kim, Hyo Jeong Lim, Amelie Boichard, Mina Nikanjam, Elizabeth Weihe, Dennis J Kuo, Ramez N Eskander, Aaron Goodman, Natalie Galanina, Paul T Fanta, Richard B Schwab, Rebecca Shatsky, Steven C Plaxe, Andrew Sharabi, Edward Stites, Jacob J Adashek, Ryosuke Okamura, Suzanna Lee, Scott M Lippman, Jason K Sicklick, Razelle Kurzrock. Nat Commun 2020
Times Cited: 66







List of co-cited articles
376 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study.
Jason K Sicklick, Shumei Kato, Ryosuke Okamura, Maria Schwaederle, Michael E Hahn, Casey B Williams, Pradip De, Amy Krie, David E Piccioni, Vincent A Miller,[...]. Nat Med 2019
233
37

Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial.
Jordi Rodon, Jean-Charles Soria, Raanan Berger, Wilson H Miller, Eitan Rubin, Aleksandra Kugel, Apostolia Tsimberidou, Pierre Saintigny, Aliza Ackerstein, Irene Braña,[...]. Nat Med 2019
196
24

Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group.
F Mosele, J Remon, J Mateo, C B Westphalen, F Barlesi, M P Lolkema, N Normanno, A Scarpa, M Robson, F Meric-Bernstam,[...]. Ann Oncol 2020
221
24

OncoKB: A Precision Oncology Knowledge Base.
Debyani Chakravarty, Jianjiong Gao, Sarah M Phillips, Ritika Kundra, Hongxin Zhang, Jiaojiao Wang, Julia E Rudolph, Rona Yaeger, Tara Soumerai, Moriah H Nissan,[...]. JCO Precis Oncol 2017
905
22

A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).
J Mateo, D Chakravarty, R Dienstmann, S Jezdic, A Gonzalez-Perez, N Lopez-Bigas, C K Y Ng, P L Bedard, G Tortora, J-Y Douillard,[...]. Ann Oncol 2018
179
21

Molecular Tumor Boards in Clinical Practice.
Claudio Luchini, Rita T Lawlor, Michele Milella, Aldo Scarpa. Trends Cancer 2020
31
41

High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial.
Christophe Massard, Stefan Michiels, Charles Ferté, Marie-Cécile Le Deley, Ludovic Lacroix, Antoine Hollebecque, Loic Verlingue, Ecaterina Ileana, Silvia Rosellini, Samy Ammari,[...]. Cancer Discov 2017
343
19

Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Christophe Le Tourneau, Jean-Pierre Delord, Anthony Gonçalves, Céline Gavoille, Coraline Dubot, Nicolas Isambert, Mario Campone, Olivier Trédan, Marie-Ange Massiani, Cécile Mauborgne,[...]. Lancet Oncol 2015
626
18

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.
Alexander Drilon, Theodore W Laetsch, Shivaani Kummar, Steven G DuBois, Ulrik N Lassen, George D Demetri, Michael Nathenson, Robert C Doebele, Anna F Farago, Alberto S Pappo,[...]. N Engl J Med 2018
18

Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists.
Marilyn M Li, Michael Datto, Eric J Duncavage, Shashikant Kulkarni, Neal I Lindeman, Somak Roy, Apostolia M Tsimberidou, Cindy L Vnencak-Jones, Daynna J Wolff, Anas Younes,[...]. J Mol Diagn 2017
735
18

Multidisciplinary molecular tumour board: a tool to improve clinical practice and selection accrual for clinical trials in patients with cancer.
Christian Rolfo, Paolo Manca, Roberto Salgado, Peter Van Dam, Amelie Dendooven, Jose Ferri Gandia, Annemie Rutten, Willem Lybaert, Joanna Vermeij, Thomas Gevaert,[...]. ESMO Open 2018
45
20

Molecular Tumor Boards: Realizing Precision Oncology Therapy.
Maulik Patel, Shumei M Kato, Razelle Kurzrock. Clin Pharmacol Ther 2018
18
44

Molecular tumor board: the University of California-San Diego Moores Cancer Center experience.
Maria Schwaederle, Barbara A Parker, Richard B Schwab, Paul T Fanta, Sarah G Boles, Gregory A Daniels, Lyudmila A Bazhenova, Rupa Subramanian, Alice C Coutinho, Haydee Ojeda-Fournier,[...]. Oncologist 2014
118
12

From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm.
Jacob J Adashek, Vivek Subbiah, Razelle Kurzrock. Trends Cancer 2021
26
30

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.
David M Hyman, Igor Puzanov, Vivek Subbiah, Jason E Faris, Ian Chau, Jean-Yves Blay, Jürgen Wolf, Noopur S Raje, Eli L Diamond, Antoine Hollebecque,[...]. N Engl J Med 2015
10

Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study.
Jennifer J Wheler, Filip Janku, Aung Naing, Yali Li, Bettzy Stephen, Ralph Zinner, Vivek Subbiah, Siqing Fu, Daniel Karp, Gerald S Falchook,[...]. Cancer Res 2016
154
10

Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal.
David Tamborero, Rodrigo Dienstmann, Maan Haj Rachid, Jorrit Boekel, Richard Baird, Irene Braña, Luigi De Petris, Jeffrey Yachnin, Christophe Massard, Frans L Opdam,[...]. Nat Med 2020
26
26

A virtual molecular tumor board to improve efficiency and scalability of delivering precision oncology to physicians and their patients.
Michael J Pishvaian, Edik M Blais, R Joseph Bender, Shruti Rao, Simina M Boca, Vincent Chung, Andrew E Hendifar, Sam Mikhail, Davendra P S Sohal, Paula R Pohlmann,[...]. JAMIA Open 2019
27
25

Molecular Tumor Boards: current practice and future needs.
D L van der Velden, C M L van Herpen, H W M van Laarhoven, E F Smit, H J M Groen, S M Willems, P M Nederlof, M H G Langenberg, E Cuppen, S Sleijfer,[...]. Ann Oncol 2017
65
10

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
Dung T Le, Jennifer N Uram, Hao Wang, Bjarne R Bartlett, Holly Kemberling, Aleksandra D Eyring, Andrew D Skora, Brandon S Luber, Nilofer S Azad, Dan Laheru,[...]. N Engl J Med 2015
10

Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials.
Maria Schwaederle, Melissa Zhao, J Jack Lee, Alexander M Eggermont, Richard L Schilsky, John Mendelsohn, Vladimir Lazar, Razelle Kurzrock. J Clin Oncol 2015
257
10

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.
Ahmet Zehir, Ryma Benayed, Ronak H Shah, Aijazuddin Syed, Sumit Middha, Hyunjae R Kim, Preethi Srinivasan, Jianjiong Gao, Debyani Chakravarty, Sean M Devlin,[...]. Nat Med 2017
10

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
E A Eisenhauer, P Therasse, J Bogaerts, L H Schwartz, D Sargent, R Ford, J Dancey, S Arbuck, S Gwyther, M Mooney,[...]. Eur J Cancer 2009
10

Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial.
O Trédan, Q Wang, D Pissaloux, P Cassier, A de la Fouchardière, J Fayette, F Desseigne, I Ray-Coquard, C de la Fouchardière, D Frappaz,[...]. Ann Oncol 2019
77
10

Rationale and Design of the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
Pam K Mangat, Susan Halabi, Suanna S Bruinooge, Elizabeth Garrett-Mayer, Ajjai Alva, Katherine A Janeway, Philip J Stella, Emile Voest, Kathleen J Yost, Jane Perlmutter,[...]. JCO Precis Oncol 2018
64
9

Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience.
Maria Schwaederle, Barbara A Parker, Richard B Schwab, Gregory A Daniels, David E Piccioni, Santosh Kesari, Teresa L Helsten, Lyudmila A Bazhenova, Julio Romero, Paul T Fanta,[...]. Mol Cancer Ther 2016
107
9


Guidance for laboratories performing molecular pathology for cancer patients.
Ian A Cree, Zandra Deans, Marjolijn J L Ligtenberg, Nicola Normanno, Anders Edsjö, Etienne Rouleau, Francesc Solé, Erik Thunnissen, Wim Timens, Ed Schuuring,[...]. J Clin Pathol 2014
116
9

Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial.
Tracy L Stockley, Amit M Oza, Hal K Berman, Natasha B Leighl, Jennifer J Knox, Frances A Shepherd, Eric X Chen, Monika K Krzyzanowska, Neesha Dhani, Anthony M Joshua,[...]. Genome Med 2016
146
9

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.
Aurélien Marabelle, Marwan Fakih, Juanita Lopez, Manisha Shah, Ronnie Shapira-Frommer, Kazuhiko Nakagawa, Hyun Cheol Chung, Hedy L Kindler, Jose A Lopez-Martin, Wilson H Miller,[...]. Lancet Oncol 2020
540
9

Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH).
Keith T Flaherty, Robert J Gray, Alice P Chen, Shuli Li, Lisa M McShane, David Patton, Stanley R Hamilton, P Mickey Williams, A John Iafrate, Jeffrey Sklar,[...]. J Clin Oncol 2020
68
9

Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-small Cell Lung Cancer.
Natasha B Leighl, Ray D Page, Victoria M Raymond, Davey B Daniel, Stephen G Divers, Karen L Reckamp, Miguel A Villalona-Calero, Daniel Dix, Justin I Odegaard, Richard B Lanman,[...]. Clin Cancer Res 2019
226
9


Clinical Outcomes of Molecular Tumor Boards: A Systematic Review.
Kara L Larson, Bin Huang, Heidi L Weiss, Pam Hull, Philip M Westgate, Rachel W Miller, Susanne M Arnold, Jill M Kolesar. JCO Precis Oncol 2021
10
60

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.
Alice T Shaw, Dong-Wan Kim, Kazuhiko Nakagawa, Takashi Seto, Lucio Crinó, Myung-Ju Ahn, Tommaso De Pas, Benjamin Besse, Benjamin J Solomon, Fiona Blackhall,[...]. N Engl J Med 2013
7

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer.
Scott Kopetz, Axel Grothey, Rona Yaeger, Eric Van Cutsem, Jayesh Desai, Takayuki Yoshino, Harpreet Wasan, Fortunato Ciardiello, Fotios Loupakis, Yong Sang Hong,[...]. N Engl J Med 2019
483
7

Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.
Sue Richards, Nazneen Aziz, Sherri Bale, David Bick, Soma Das, Julie Gastier-Foster, Wayne W Grody, Madhuri Hegde, Elaine Lyon, Elaine Spector,[...]. Genet Med 2015
7

Molecular profiling for precision cancer therapies.
Eoghan R Malone, Marc Oliva, Peter J B Sabatini, Tracy L Stockley, Lillian L Siu. Genome Med 2020
181
7

Variant classification in precision oncology.
Jonas Leichsenring, Peter Horak, Simon Kreutzfeldt, Christoph Heining, Petros Christopoulos, Anna-Lena Volckmar, Olaf Neumann, Martina Kirchner, Carolin Ploeger, Jan Budczies,[...]. Int J Cancer 2019
28
17

Cancer Statistics, 2021.
Rebecca L Siegel, Kimberly D Miller, Hannah E Fuchs, Ahmedin Jemal. CA Cancer J Clin 2021
7

Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB).
Christian Rolfo, Andrés F Cardona, Massimo Cristofanilli, Luis Paz-Ares, Juan Jose Diaz Mochon, Ignacio Duran, Luis E Raez, Alessandro Russo, Jose A Lorente, Umberto Malapelle,[...]. Crit Rev Oncol Hematol 2020
44
11

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
Dung T Le, Jennifer N Durham, Kellie N Smith, Hao Wang, Bjarne R Bartlett, Laveet K Aulakh, Steve Lu, Holly Kemberling, Cara Wilt, Brandon S Luber,[...]. Science 2017
7

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers.
Aaron M Goodman, Shumei Kato, Lyudmila Bazhenova, Sandip P Patel, Garrett M Frampton, Vincent Miller, Philip J Stephens, Gregory A Daniels, Razelle Kurzrock. Mol Cancer Ther 2017
7

Key Lessons Learned from Moffitt's Molecular Tumor Board: The Clinical Genomics Action Committee Experience.
Todd C Knepper, Gillian C Bell, J Kevin Hicks, Eric Padron, Jamie K Teer, Teresa T Vo, Nancy K Gillis, Neil T Mason, Howard L McLeod, Christine M Walko. Oncologist 2017
45
11

The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs.
D L van der Velden, L R Hoes, H van der Wijngaart, J M van Berge Henegouwen, E van Werkhoven, P Roepman, R L Schilsky, W W J de Leng, A D R Huitema, B Nuijen,[...]. Nature 2019
80
7

Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval.
Denis L Jardim, Maria Schwaederle, Caimiao Wei, J Jack Lee, David S Hong, Alexander M Eggermont, Richard L Schilsky, John Mendelsohn, Vladimir Lazar, Razelle Kurzrock. J Natl Cancer Inst 2015
119
7

Hallmarks of cancer: the next generation.
Douglas Hanahan, Robert A Weinberg. Cell 2011
7

Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing.
Garrett M Frampton, Alex Fichtenholtz, Geoff A Otto, Kai Wang, Sean R Downing, Jie He, Michael Schnall-Levin, Jared White, Eric M Sanford, Peter An,[...]. Nat Biotechnol 2013
6

Multicenter Comparison of Molecular Tumor Boards in The Netherlands: Definition, Composition, Methods, and Targeted Therapy Recommendations.
Bart Koopman, Harry J M Groen, Marjolijn J L Ligtenberg, Katrien Grünberg, Kim Monkhorst, Adrianus J de Langen, Mirjam C Boelens, Marthe S Paats, Jan H von der Thüsen, Winand N M Dinjens,[...]. Oncologist 2021
9
44

COSMIC: the Catalogue Of Somatic Mutations In Cancer.
John G Tate, Sally Bamford, Harry C Jubb, Zbyslaw Sondka, David M Beare, Nidhi Bindal, Harry Boutselakis, Charlotte G Cole, Celestino Creatore, Elisabeth Dawson,[...]. Nucleic Acids Res 2019
6


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.